Related Experiment Video
Updated: Jun 21, 2026
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
A high-throughput method to identify novel senescence-inducing compounds
Jonathan A Ewald1, Noel Peters, Joshua A Desotelle
1Department of Urology, University of Wisconsin-Madison, Madison, Wisconsin 53792, USA.
Abstract:
Cellular senescence is a persistently growth-arrested phenotype in normal and transformed cells induced by noncytotoxic stress. Cytostasis as a method of cancer treatment has recently generated significant interest. Research into the induction of cellular senescence as cancer therapy has been hindered by a lack of compounds that efficiently induce this response. The authors describe a semiautomated high-throughput method to identify library compounds that induce senescence using prostate cancer cells cultured in 96-well plates. Primary hits are identified by low cell numbers after 3 days in culture, measured by Hoechst 33342 fluorescence. A secondary visual assessment of senescence-associated beta-galactosidase staining and cellular morphology in the same wells distinguishes senescence from quiescence, apoptosis, and other false positives. This method was used to screen a 4160-compound library of known bioactive compounds and natural products at a 10-microM dose. Candidate compounds were further selected based on persistent growth arrest after drug removal and increased expression of previously described senescence marker genes. Four lead compounds not previously associated with senescence were identified for further investigation. This is the first successful assay to identify novel agents from compound libraries based on senescence induction in cancer cells.
Insights
Researchers developed a new method to find compounds that trigger cellular senescence, a key process for cancer therapy. This high-throughput screening identified four novel compounds for further study in cancer treatment.
Area of Science:
- Oncology
- Cell Biology
- Drug Discovery
Background:
- Cellular senescence is a stable cell cycle arrest that holds promise for cancer therapy.
- Inducing cellular senescence as a cancer treatment strategy is gaining interest but lacks efficient methods.
- Identifying novel compounds that reliably induce senescence has been a significant challenge.
Purpose of the Study:
- To develop and validate a high-throughput screening method for identifying compounds that induce cellular senescence in cancer cells.
- To screen a diverse library of known bioactive compounds and natural products for senescence-inducing agents.
- To identify novel lead compounds that can be further investigated for their therapeutic potential in cancer treatment.
Main Methods:
- A semiautomated, 96-well plate-based assay was designed to screen compound libraries.
- Primary hits were identified by measuring low cell numbers using Hoechst 33342 fluorescence after 3 days.
- Secondary validation involved senescence-associated beta-galactosidase staining and morphological assessment to distinguish senescence from other cellular fates.
Main Results:
- A library of 4160 compounds was screened at a 10-microM dose.
- The assay successfully identified compounds inducing persistent growth arrest and increased expression of senescence markers.
- Four novel lead compounds, not previously linked to senescence, were identified for further research.
Conclusions:
- A robust high-throughput screening method for identifying senescence-inducing compounds in cancer cells has been established.
- This assay represents a significant advancement in the discovery of novel cancer therapeutics targeting cellular senescence.
- The identified lead compounds offer promising avenues for developing new anti-cancer strategies based on senescence induction.
